Search Patents
  • Multispecific antibodies against CD40 and CD137
    Patent number: 11440966
    Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.
    Type: Grant
    Filed: June 11, 2021
    Date of Patent: September 13, 2022
    Assignees: GENMAB A/S, BIONTECH SE
    Inventors: Isil Altintas, David Satijn, Rik Rademaker, Paul Parren, Friederike Gieseke, Ugur Sahin
  • Modification of RNA, producing an increased transcript stability and translation efficiency
    Patent number: 10106800
    Abstract: It was the object of the present invention to provide RNA with increased stability and translation efficiency and means for obtaining such RNA. It should be possible to obtain increased grades of expression by using said RNA in gene therapy approaches.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: October 23, 2018
    Assignee: BioNTech AG
    Inventors: Ugur Sahin, Silke Holtkamp, Ozlem Tureci, Sebastian Kreiter
  • RECOMBINANT VACCINES AND USE THEREOF
    Publication number: 20220257783
    Abstract: The present invention relates to fusion molecules of antigens, the nucleic acids coding therefor and the use of such fusion molecules and nucleic acids. In particular, said invention relates to fusion molecules, comprising an antigen and the trans-membrane region and cytoplasmic region of a MHC molecule and/or the cytoplasmic region of a MHC or a SNARE molecule.
    Type: Application
    Filed: March 7, 2022
    Publication date: August 18, 2022
    Inventors: Ozlem Tureci, Ugur Sahin, Sebastian Kreiter
  • CLAUDIN-18.2-SPECIFIC IMMUNORECEPTORS AND T CELL EPITOPES
    Publication number: 20180282389
    Abstract: The present invention provides Claudin-18.2-specific immunoreceptors (T cell receptors and artificial T cell receptors (chimeric antigen receptors; CARs)) and T cell epitopes which are useful for immunotherapy.
    Type: Application
    Filed: May 9, 2016
    Publication date: October 4, 2018
    Inventors: Ugur SAHIN, Ozlem TÜRECI, Petra SIMON, Tana OMOKOKO, Andrea BREITKREUZ, Karolina Anna MROZ, Lisa HEBICH
  • Recombinant Vaccines and Use Thereof
    Publication number: 20180177885
    Abstract: The present invention relates to fusion molecules of antigens, the nucleic acids coding therefor and the use of such fusion molecules and nucleic acids. In particular, said invention relates to fusion molecules, comprising an antigen and the trans-membrane region and cytoplasmic region of a MHC molecule and/or the cytoplasmic region of a MHC or a SNARE molecule.
    Type: Application
    Filed: February 13, 2018
    Publication date: June 28, 2018
    Applicant: BioNTech AG
    Inventors: Ozlem Tureci, Ugur Sahin, Sebastian Kreiter
  • Monoclonal antibodies for treatment of cancer
    Patent number: 8354104
    Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing GT468, including tumor-related diseases such as breast cancer, lung cancer, gastric cancer, ovarian cancer, and hepatocellular cancer.
    Type: Grant
    Filed: March 14, 2008
    Date of Patent: January 15, 2013
    Assignees: Ganymed Pharmaceuticals AG, Johannes Gutenberg—Universitat
    Inventors: Ugur Sahin, Michael Koslowski, Ozlem Tureci
  • Compositions and methods for diagnosis and treatment of cancer
    Patent number: 10370433
    Abstract: The present invention relates to the diagnosis and treatment of cancerous diseases, in particular cancerous diseases expressing Seprase (Fap-alpha; fibroblast activation protein alpha). More particularly, the invention concerns peptides targeting Seprase.
    Type: Grant
    Filed: March 15, 2016
    Date of Patent: August 6, 2019
    Assignee: Biontech AG
    Inventors: Ugur Sahin, Joycelyn Wüstehube-Lausch, Markus Fiedler, Matin Daneschdar, Hans-Ulrich Schmoldt
  • Multispecific antibodies against CD40 and CD137
    Patent number: 11084882
    Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.
    Type: Grant
    Filed: April 22, 2020
    Date of Patent: August 10, 2021
    Assignees: GENMAB A/S, BIONTECH SE
    Inventors: Isil Altintas, David Satijn, Rik Rademaker, Paul Parren, Friederike Gieseke, Ugur Sahin
  • COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER
    Publication number: 20190298803
    Abstract: The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as pancreatic cancer and metastases thereof.
    Type: Application
    Filed: May 2, 2019
    Publication date: October 3, 2019
    Inventors: Ugur Sahin, Ozlem Tureci, Rita Mitnacht-Kraus, Stefan Woll, Stefan Jacobs, Cornelia Heinz
  • COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER
    Publication number: 20210023177
    Abstract: The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as pancreatic cancer and metastases thereof.
    Type: Application
    Filed: October 8, 2020
    Publication date: January 28, 2021
    Inventors: Ugur Sahin, Ozlem Tureci, Rita Mitnacht-Kraus, Stefan Woll, Stefan Jacobs, Cornelia Heinz
  • METHODS AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF CANCER
    Publication number: 20190169614
    Abstract: The present invention relates to the identification of nucleic acid and amino acid sequences that are characteristic of tumor tissues such as ovarian tumor and lung tumor tissues and which represent targets for therapy or diagnosis of tumor diseases in a subject.
    Type: Application
    Filed: February 13, 2019
    Publication date: June 6, 2019
    Inventors: Ugur Sahin, Özlem Tureci, Michael Koslowski, Gerd Helftenbein, Korden Walter, Stefan Woll, Gabriela-Elena Oprea
  • Tumor Antigens for Determining Cancer Therapy
    Publication number: 20230355732
    Abstract: The present invention relates to the treatment of cancer, in particular breast cancer, particularly triple-negative breast cancer. More particularly, the invention concerns methods and means for cancer treatment involving a specific set of tumor antigens.
    Type: Application
    Filed: February 28, 2023
    Publication date: November 9, 2023
    Inventors: Ugur Sahin, Claudia Paret, Kirsten Vormbrock, Christian Bender, Petra Simon, Christoph Hartmann, Stefanie Hubich, Thomas Bukur, Thorsten Litzenberger
  • METHODS AND COMPOSITIONS FOR STIMULATING IMMUNE RESPONSE
    Publication number: 20230074462
    Abstract: The present invention relates to methods and compositions for stimulating an immune response. In particular, the present invention relates to immunostimulatory RNA molecules comprising sequences derived from an Influenza A virus nucleoprotein-encoding RNA molecule that act as adjuvants and/or immunostimulatory agents to enhance host immune responses.
    Type: Application
    Filed: September 12, 2022
    Publication date: March 9, 2023
    Inventors: Mahjoub Bihi, Ugur Sahin, Mustafa Diken, Thorsten Klamp
  • TUMOR ANTIGENS FOR DETERMINING CANCER THERAPY
    Publication number: 20190192643
    Abstract: The present invention relates to the treatment of cancer, in particular breast cancer, particularly triple-negative breast cancer. More particularly, the invention concerns methods and means for cancer treatment involving a specific set of tumor antigens.
    Type: Application
    Filed: December 21, 2018
    Publication date: June 27, 2019
    Inventors: Ugur Sahin, Claudia Paret, Kirsten Vormbrock, Christian Bender, Petra Simon, Christoph Hartmann, Stefanie Hubich, Thomas Bukur, Thorsten Litzenberger
  • COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER
    Publication number: 20180000900
    Abstract: The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as pancreatic cancer and metastases thereof.
    Type: Application
    Filed: August 23, 2017
    Publication date: January 4, 2018
    Inventors: Ugur Sahin, Ozlem Tureci, Rita Mitnacht-Kraus, Stefan Woll, Stefan Jacobs, Cornelia Heinz
  • CHIMERIC ANTIGEN RECEPTOR-MODIFIED CELLS FOR THE TREATMENT OF CLDN6-EXPRESSING CANCERS
    Publication number: 20220184119
    Abstract: The present disclosure relates to a chimeric antigen receptor (CAR) showing highly specific and sensitive recognition of CLDN6 expressing target cells as well as a high potential for survival and repetitive stimulation of CAR T cells.
    Type: Application
    Filed: February 5, 2020
    Publication date: June 16, 2022
    Inventors: Ugur SAHIN, Petra OEHM, Benjamin RENGSTL, Katharina REINHARD, Kristina MICHEL
  • Identification of tumor-associated antigens for diagnosis and therapy
    Patent number: 9919036
    Abstract: The invention relates to genetic products the expression of which is associated with cancer diseases. The invention also relates to the therapy and diagnosis of diseases in which the genetic products are expressed or aberrantly expressed, in particular cancer diseases.
    Type: Grant
    Filed: January 27, 2015
    Date of Patent: March 20, 2018
    Assignees: GANYMED PHARMACEUTICALS AG, JOHANNES GUTENBERG-UNIVERSITAT MAINZ
    Inventors: Ugur Sahin, Ozlem Tureci, Michael Koslowski, Dirk Usener
  • Modification of RNA, producing an increased transcript stability and translation efficiency
    Patent number: 9476055
    Abstract: It was the object of the present invention to provide RNA with increased stability and translation efficiency and means for obtaining such RNA. It should be possible to obtain increased grades of expression by using said RNA in gene therapy approaches.
    Type: Grant
    Filed: September 28, 2006
    Date of Patent: October 25, 2016
    Assignee: BIONTECH AG
    Inventors: Ugur Sahin, Silke Holtkamp, Özlem Türeci, Sebastian Kreiter
  • Identification of tumor-associated markers for diagnosing or monitoring ovarian cancer
    Patent number: 9175088
    Abstract: The present technology relates to genetic products the expression of which is associated with cancer diseases. The present technology also relates to the therapy and diagnosis of diseases in which the genetic products are expressed or aberrantly expressed, in particular cancer diseases.
    Type: Grant
    Filed: April 22, 2010
    Date of Patent: November 3, 2015
    Assignee: BIONTECH AG
    Inventors: Ugur Sahin, Özlem Türeci, Michael Koslowski
  • METHODS AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF CANCER
    Publication number: 20180119146
    Abstract: The present invention relates to the identification of nucleic acid and amino acid sequences that are characteristic of tumor tissues such as ovarian tumor and lung tumor tissues and which represent targets for therapy or diagnosis of tumor diseases in a subject.
    Type: Application
    Filed: October 5, 2017
    Publication date: May 3, 2018
    Inventors: Ugur Sahin, Özlem Türeci, Michael Koslowski, Gerd Helftenbein, Korden Walter, Stefan Wöll, Gabriela-Elena Oprea
Narrow Results

Filter by US Classification